IRMD

IRMD

USD

iRadimed Corporation Common Stock

$53.320+0.780 (1.485%)

リアルタイム価格

Healthcare
医療機器
米国

価格チャート

主要指標

市場指標
企業ファンダメンタルズ
取引統計

市場指標

始値

$52.540

高値

$53.640

安値

$50.620

出来高

0.00M

企業ファンダメンタルズ

時価総額

678.0M

業種

医療機器

United States

取引統計

平均出来高

0.04M

取引所

NGM

通貨

USD

52週レンジ

安値 $40.55現在値 $53.320高値 $63.29

AI分析レポート

最終更新: 2025年4月20日
AIによる生成データソース: Yahoo Finance, Bloomberg, SEC

[IRMD: iRadimed Corporation Common Stock]: Decoding Recent Moves & Potential Paths Forward

Stock Symbol: IRMD Generate Date: 2025-04-20 09:00:13

Alright, let's take a look at iRadimed (IRMD). This is a company in the medical devices space, specifically MRI-compatible stuff. Think pumps and monitoring systems for patients in MRI machines. Interesting niche. So, what's been going on with their stock lately?

Recent News Buzz: Good Vibes from the Analysts

First off, the news front seems pretty positive, at least from the analyst side. Back in February, Roth MKM, a firm you might hear about, came out and basically said, "We still like this stock." Not only that, they bumped up their price target. They were thinking $60 before, now they're saying $72. That's a decent jump. So, at least one group of experts is feeling pretty good about iRadimed's prospects. This kind of "reiteration" with a higher target usually signals confidence in the company's future.

Price Check - What's Been Happening on the Chart?

Now, let's peek at the stock price itself. Looking back over the last month or so, it's been a bit of a rollercoaster, honestly. If you rewind to late January and early February, the stock was hanging around the $60 mark, give or take. Then, around mid-February (right around when that positive analyst note came out, actually), things took a turn downwards. We saw a pretty noticeable drop, and the price has generally been trending lower since then, hitting the low $50s in early April.

However, it's not all doom and gloom. If you look closer at the very recent price action, say in the last couple of weeks, it seems like the stock might be trying to find its footing. We've seen a bit of a bounce back from those lows in early April. The previous close was around $51.96. So, while the overall trend in the last month hasn't been great, there are hints of stabilization, maybe even a little upward momentum trying to build.

Interestingly, the AI prediction models are quite optimistic for the very short term. They're forecasting the price to jump up by around 3-4% today and in the next couple of days. That's a pretty bullish short-term outlook from the AI side.

Putting It All Together - What's the Play?

Okay, so we've got positive analyst sentiment, a recent price dip followed by potential stabilization, and AI models predicting a short-term bump. What does this all mean for someone looking at this stock?

It's a bit of a mixed bag, to be honest. The analyst upgrade and AI predictions suggest there could be some upside potential here. The fact that a firm like Roth MKM reiterated their "Buy" rating and raised their target is definitely a positive signal. And those AI forecasts, while you should always take them with a grain of salt, are pointing towards a potential near-term rise.

  • Near-Term Leaning: Given the positive news and AI predictions, and the recent price stabilization, the situation might be leaning slightly towards a potential 'buy' or 'accumulate' scenario for the short-term, if you believe in the AI's short-term forecast and the analyst's longer-term view. However, the recent downward price trend is a caution flag.

  • Potential Entry Consideration: If you're thinking about getting in, the current price area around $52 might be worth considering. It's near the recent lows, and if the AI predictions are right, you could see a quick pop. Plus, the recommendation data mentions a support level around $51.65, so buying near there could offer some downside protection. But, and this is important, watch for confirmation that this recent stabilization is real and not just a temporary pause in the downtrend.

  • Potential Exit/Stop-Loss Consideration: For taking profits, you could look at the AI's predicted price targets for the next few days. Or, if you're thinking longer-term, the analyst's $72 target is way up there, but might be a bit optimistic in the immediate future. A more realistic near-term profit target might be somewhere in the $55-$60 range, if the stock can regain some of its previous levels. For a stop-loss, to manage risk, you could consider placing it below recent lows, perhaps around $48-$49. This is just a thought, and depends on your risk tolerance. Remember, stop-losses are there to protect you if things go south.

Company Snapshot: MRI Niche Player

Just a quick reminder about the company itself. iRadimed is focused on a specific area within medical devices – making equipment that works safely inside MRI machines. This is a specialized market, and they seem to be a key player in it. They're not a giant company, with around 160 employees and a market cap in the mid-hundreds of millions. So, it's a smaller, potentially higher-growth type of stock, which can also mean more volatility.

In a nutshell: IRMD is showing some interesting signals. Positive analyst vibes and optimistic AI predictions are countered by a recent price dip. It's a situation that might warrant a closer look, especially if you're comfortable with a bit of risk and are interested in the medical device sector. Keep an eye on the price action to see if this recent stabilization turns into a more sustained upward move.


Disclaimer: This analysis is for informational purposes only and should not be considered financial advice. I am just breaking down publicly available data and offering potential interpretations. Investing in the stock market involves risk, and you could lose money. Always do your own thorough research and consider consulting with a qualified financial advisor before making any investment decisions.

関連ニュース

Analyst Upgrades

Roth MKM Reiterates Buy on iRadimed, Raises Price Target to $72

Roth MKM analyst Jason Wittes reiterates iRadimed with a Buy and raises the price target from $60 to $72.

もっと見る
Roth MKM Reiterates Buy on iRadimed, Raises Price Target to $72

AI予測Beta

AI推奨

強気

更新日時: 2025年4月27日 17:05

弱気中立強気

70.7% 信頼度

リスクと取引

リスクレベル3/5
中リスク
適しているのは
中程度
取引ガイド

エントリーポイント

$52.29

利確

$54.51

損切り

$48.10

主要因子

PDI 28.7はMDI 24.2の上にあり、ADX 8.6とともに強気トレンドを示唆しています
出来高は平均(1,039)の1.8倍で、市場参加の増加を示しています
MACD 0.1791はシグナルライン0.0838の上にあり、強気クロスオーバーを示しています

最新情報を入手

価格アラートを設定し、AI分析の更新とリアルタイム市場ニュースを受け取る。